^
Association details:
| Biomarker: | NOTCH2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P14.13 - Notch Family Gene Mutations Predict Clinical Benefit from Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
Published date:
01/12/2021
Excerpt:
250 (17.36%) of the NSCLC patients had Notch mutation. In the ICI-treated cohort, patients with Notch mutation had longer OS (median OS, 22.00 vs 11.15 months...NSCLC patients with Notch mutation especially those with more Notch mutations get longer OS and better response in ICI treatment, making Notch mutation a positive predictive biomarker.
Source:
Title:
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
Published date:
08/08/2020
Excerpt:
...we confirmed the relationship between the NOTCHmut/HRmut signature and longer progression-free survival (PFS) in ICI-treated patients (multivariate Cox: HR 0.51, 95% CI 0.34 to 0.76, p=0.001). The NOTCHmut/HRmut genomic predictor was also associated with longer survival (log-rank p=0.008), despite patients whose tumors carried the NOTCHmut/HRmut signature had higher metastatic burden as compared with their negative counterpart.
DOI:
10.1136/jitc-2020-000946
